Pharmaceutical From Standard to Specialist Capsule Formats Hard gelatin, HPMC, inhalation and vaginal formats engineered for every therapeutic need. View all →
Nutraceutical Consumer-Ready Nutraceutical Formats Capsules and branded ingredients built for supplement manufacturers who demand differentiation. Explore range →
Advanced Formulation Beyond the Standard Capsule Liquid-fill, dual-release and multiparticulate technologies for complex formulations. Explore technologies →
Innovation Always One Step Ahead in Drug Delivery Latest equipment, services and technology partnerships to keep production at the cutting edge. Discover what's new →
CDMO Partnership
From concept to market-ready product — your end-to-end nutraceutical development partner.
Pharmaceutical CDMO
Our Innovaform Accelerator and Tampa facility combine formulation science with scalable manufacturing.
Our Story
A global leader in capsule technologies, committed to advancing pharmaceutical and nutraceutical science.
Basel, Switzerland, 7 February 2018 – Lonza, one of the world's leading suppliers to the pharmaceutical, biotech and specialty ingredients industries, announced today that it has launched a venture capital fund to back emerging consumer-health companies in North America.
The Prolog Lonza Consumer Fund will focus on products, technologies and innovative business models related to fast-moving consumer goods markets, such as personal care, functional food and beverages, medical food, dietary supplements and home care. The emphasis will be on products that maintain, protect or preserve the health and well-being of people and companion animals around the world through proprietary ingredients, formulations and delivery technologies.
U.S.-based Prolog Ventures has been named the fund's manager for investments in innovative early-stage, fast-growing consumer health and wellness startups in North America.
The newly created fund offers value well beyond financial support by leveraging Lonza's global resources and expertise to accelerate the growth of its portfolio companies. It is expected that the fund will invest annually into two or three startups on average in the mid-single-digit million-dollar range.
"This investment demonstrates Lonza's commitment to innovating along the value chain and to creating additional value for our customers with new technologies and integrated solutions," said Sven Abend, COO of Lonza's Specialty Ingredients segment.